Management attributes the increased net loss primarily to non-cash fair value adjustments of warrant liabilities from the ...

Who’s gaining ground?: Arrowhead, Legend, and Kura reported strong product launches, with rising prescriptions, expanding markets, and competitive positioning against rivals. What’s next in trials?: ...

Management View "We continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma" and said the TakeAi ...

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., May 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused ...

Thank you, and welcome to the Curis First Quarter 2026 Business Update Call. Before we begin, I'd like to encourag ...

Curis, Inc. , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and ...

Curis Inc. (CRIS) on Tuesday reported a loss of $24.2 million in its first quarter. The Lexington, Massachusetts-based company said it had a loss of $1.

Curis (CRIS) is scheduled to announce Q1 earnings results on Tuesday, May 12th, after market close. The consensus EPS Estimate is -$0.29 (+76.8% Y/Y) and the consensus Revenue Estimate is $1.86M (-21.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company ...

Vernal 2026,' a spring-inspired contemporary arts exhibition, is on display at Buffalo Prescott’s Detroit headquarters ...

With the grand reopening of MOCAD—and a thriving, ever-growing gallery scene—a trip to Detroit should be on every art ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.